Therapy News and Research

RSS

Many Huntington's disease patients suffer from weight loss, sleeping problems

An aggregating protein causes many of the symptoms of Huntington's disease, an incurable and frequently fatal brain disorder. Mosaic winner Ahmad Aziz discovered that the abnormal protein also aggregates in the hypothalamus, the part of the brain that regulates the autonomic nervous system and the endocrine system.

16 Jun 2010

New online smoking-cessation study launched

Fred Hutchinson Cancer Research Center announced today that it is launching a new online study to help people quit smoking. The study, called WebQuit, is enrolling adult smokers nationwide. Participation is free to eligible individuals.

16 Jun 2010

Norgine to develop and commercialize Tranzyme's ulimorelin ghrelin agonist

Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.

16 Jun 2010

Dutch researcher investigates causes and consequences of insomnia

The brains of older adults with chronic sleep problems look different from those of adults who have enjoyed enough sleep. Yet the older adults function well despite their lack of sleep. They switch to a continuous form of mild stress, as a result of which they sometimes even perform better than contemporaries who enjoy a good night's sleep says Dutch researcher Ellemarije Altena.

16 Jun 2010

European market for continuous glucose monitoring to reach $52M in 2016

The continuous glucose monitoring (CGM) market is in its development stage. The primary factor leading to the growth of the (CGM) market in Europe is the need for an easy-to-use and patient-friendly glucose-monitoring device. The traditional method of monitoring glucose was difficult and inconvenient for patients. The CGM method is not only hassle-free, but also gives a better diagnosis of diabetes.

16 Jun 2010

Exercise helps patients recover shoulder movement after breast cancer surgery

An active 72-year-old woman, Claire Mitchell had always enjoyed cooking. However, after breast cancer surgery she found that she had less freedom of movement and reaching jars on high shelves became quite painful. Her plight is common.

16 Jun 2010

Diabetes associated with increased risk of cancer

A new consensus statement of experts assembled by the American Diabetes Association and the American Cancer Society reviews emerging evidence that suggests cancer incidence is associated with diabetes as well as certain diabetes risk factors and treatments. The new report reviews the state of science concerning the association between diabetes and cancer incidence/prognosis; risk factors common to both diseases; possible biologic links between diabetes and cancer risk; and whether diabetes treatments influence the risk of cancer or cancer prognosis.

16 Jun 2010

Combination of BRAF-targeted therapy and immunotherapy shows promise for treatment of melanoma

Combined targeted therapy against the BRAF/MAPK pathway with immunotherapy shows promise as a new therapeutic approach for the treatment of melanoma, according to results of a preclinical study published in Cancer Research, a journal of the American Association for Cancer Research.

16 Jun 2010

Newly published research examines association between CKD and CYP24

Cytochroma today announced the publication of new data from studies in a preclinical model indicating that chronic kidney disease is associated with markedly increased expression of the vitamin D catabolic enzyme, CYP24, which contributes to vitamin D insufficiency and resistance to vitamin D therapy. Parallel analysis of kidney biopsies obtained from CKD patients confirmed abnormal CYP24 expression in human disease as well.

16 Jun 2010

Study aims at determining optimal dose of nab-paclitaxel with carboplatin as first-line therapy for NSCLC

The June edition of the Journal of Thoracic Oncology features a study aimed at determining the optimal dose of the chemotherapy drug nab-paclitaxel with carboplatin as a first-line therapy in patients with non-small cell lung cancer. Results will provide researchers with a data needed to guide a phase 3 trial.

16 Jun 2010

European Commission grants Orphan Medicinal Product Designation for QPI-1002

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that the European Commission has granted Orphan Medicinal Product Designation for QPI-1002 (also referred to as "I5NP") for the prophylaxis of delayed graft function in kidney transplant patients.

16 Jun 2010

UT Southwestern head and neck cancer surgeons perform area's first transoral robotic surgery

Head and neck cancer surgeons at UT Southwestern Medical Center performed the area's first transoral robotic surgery (TORS), a recently approved minimally invasive no-scar procedure to remove tumors in the throat.

16 Jun 2010

Florida Advisory Council on Radiation Protection endorses ASTRO's Target Safely patient protection plan

Through a unanimous decision, the Florida Advisory Council on Radiation Protection has endorsed Target Safely, the American Society for Radiation Oncology's (ASTRO) patient protection plan.

16 Jun 2010

Final results from Visudyne Phase IIIb DENALI study presented at World Ophthalmology Congress

QLT Inc. today announced that final results from the Novartis-sponsored Phase IIIb DENALI study were presented on June 8, 2010 during the World Ophthalmology Congress in Berlin. DENALI was a 24-month randomized, double-masked, multicenter trial in patients with subfoveal choroidal neovascularization secondary to wet age-related macular degeneration (all lesion types).

16 Jun 2010

New combination appears to be effective against cancer stem cells in pancreatic cancer

The new cancer medication sorafenib looks promising. Sorafenib is used for advanced liver and kidney cancer and also appears to be effective against cancer stem cells in pancreatic cancer. The team led by Professor Dr. Ingrid Herr, Head of the Department of Molecular Oncosurgery, a group of the Department of Surgery at Heidelberg University Hospital, (Managing Director: Professor Dr. Markus W. B-chler) in cooperation with the German Cancer Research Center, tested the new substance in mice and pancreatic cancer cells.

16 Jun 2010

Immunomedics initiates dosing in milatuzumab-doxorubicin conjugate Phase I/II trial for relapsed multiple myeloma

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced the dosing of the first patient in a Phase I/II clinical trial of the doxorubicin conjugate of milatuzumab for the treatment of patients with relapsed multiple myeloma.

16 Jun 2010

LMBRI, Lipopharma Therapeutics collaborate to promote cancer drug development, improve patient outcomes

LMBRI LLC and Lipopharma Therapeutics SL today announced collaboration aimed at transforming cancer drug development and improving patient outcomes. Lipopharma developed new assessment approaches, methods and technologies for developing cancer therapeutics and diagnostics using their proprietary design of structure-based molecules that regulate the structure and functions of the membrane lipids, instead targeting cellular proteins, called "Membrane Lipid-Therapy".

16 Jun 2010

Galera Therapeutics completes Series 1 financing

Galera Therapeutics, a drug development company focused on novel therapeutics to protect against the side effects and increase the effectiveness of cancer treatment, today announced it has completed a Series 1 financing led by BioGenerator. Also participating in the round is Galera Angels, LLC, an angel investment group, and Analytical Bio-Chemistry Laboratories, Inc., of Columbia Missouri.

16 Jun 2010

FDA clears Halt 2000GI Electrosurgical System for soft tissue ablation

Halt Medical, Inc., today announced that the U.S. Food and Drug Administration (FDA) has cleared the Halt 2000GI™ Electrosurgical System for soft tissue ablation using radiofrequency energy. "This clearance to market is a major milestone for our customers, employees and investors," said Russ DeLonzor, President and Chief Operating Officer.

16 Jun 2010

TYRX successfully implants AIGISRx device in 10,000 patients in the U.S.

TYRX, Inc. announced today that it has successfully implanted its AIGISRx device in 10,000 patients in the United States. The AIGISRx device is an antibacterial mesh technology that securely holds a pacemaker or implantable cardioverter defibrillator in place to create a stable environment, while delivering antimicrobial agents, rifampin and minocycline. These antimicrobial agents have been shown to reduce infections associated with medical devices in multiple randomized controlled trials.

15 Jun 2010

Therapy News and Research

Many Huntington's disease patients suffer from weight loss, sleeping problems

New online smoking-cessation study launched

Norgine to develop and commercialize Tranzyme's ulimorelin ghrelin agonist

Dutch researcher investigates causes and consequences of insomnia

European market for continuous glucose monitoring to reach $52M in 2016

Exercise helps patients recover shoulder movement after breast cancer surgery

Diabetes associated with increased risk of cancer

Combination of BRAF-targeted therapy and immunotherapy shows promise for treatment of melanoma

Newly published research examines association between CKD and CYP24

Study aims at determining optimal dose of nab-paclitaxel with carboplatin as first-line therapy for NSCLC

European Commission grants Orphan Medicinal Product Designation for QPI-1002

UT Southwestern head and neck cancer surgeons perform area's first transoral robotic surgery

Florida Advisory Council on Radiation Protection endorses ASTRO's Target Safely patient protection plan

Final results from Visudyne Phase IIIb DENALI study presented at World Ophthalmology Congress

New combination appears to be effective against cancer stem cells in pancreatic cancer

Immunomedics initiates dosing in milatuzumab-doxorubicin conjugate Phase I/II trial for relapsed multiple myeloma

LMBRI, Lipopharma Therapeutics collaborate to promote cancer drug development, improve patient outcomes

Galera Therapeutics completes Series 1 financing

FDA clears Halt 2000GI Electrosurgical System for soft tissue ablation

TYRX successfully implants AIGISRx device in 10,000 patients in the U.S.

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News